T Cell Receptor Modification for Vaccine Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines are ineffective for infectious diseases and cancers that require T cell-mediated immunity, particularly in individuals with compromised immune systems, as they lack T cells expressing specific T cell receptors that recognize vaccine antigens.
Innovation Solution
Genetically modifying T cells to express T cell receptors (TCRs) that recognize vaccine antigens using polynucleotides encoded in nanoparticles, which include carrier molecules, coatings, and targeting agents for selective delivery to T cells, enhancing T cell-mediated immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard vaccines are administered to individuals with compromised immune systems, then the vaccine formulation is delivered, but the vaccine fails to produce effective T cell-mediated immunity because these individuals lack T cells expressing specific TCRs that recognize vaccine antigens
Solution Approach 1:
The patent applies preliminary action by genetically modifying T cells before vaccine administration to express TCRs that recognize vaccine antigens. This pre-programming ensures that when the vaccine is administered, the T cells are already equipped with the specific receptors needed to recognize and respond to the antigen, eliminating the problem of lacking TCR diversity in compromised immune systems
Solution Approach 2:
The patent uses an intermediary approach by introducing exogenous TCR genes into T cells. These introduced TCRs act as intermediaries that bridge the gap between the vaccine antigen and the immune response, enabling T cells in individuals with compromised immune systems to recognize and respond to antigens they would otherwise be unable to detect
2Reliability
If T cells are genetically modified to express specific TCRs, then T cell-mediated immunity is enhanced, but the complexity of the vaccine system increases due to the need for polynucleotide delivery mechanisms
Solution Approach 1:
The patent applies universality by using a multi-functional nanoparticle system that simultaneously performs multiple tasks: protecting the polynucleotide from degradation, facilitating cellular uptake, enabling specific T cell targeting, and promoting gene expression. This consolidates multiple complex functions into a single integrated delivery platform
Solution Approach 2:
The nanoparticle acts as an intermediary that mediates the complex process of getting polynucleotides into T cells. It serves as a bridge between the external vaccine formulation and the internal cellular machinery, simplifying the overall system by handling the complexity of delivery, protection, and targeted release in a single component
Data Source
AI summary
Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.